company background image
BMRN

BioMarin PharmaceuticalNasdaqGS:BMRN Stock Report

Last Price

US$84.65

Market Cap

US$15.5b

7D

-6.2%

1Y

-3.8%

Updated

21 Jan, 2022

Data

Company Financials +
BMRN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health5/6
Dividends0/6

BMRN Stock Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

BioMarin Pharmaceutical Competitors

Moderna

NasdaqGS:MRNA

US$64.9b

Alnylam Pharmaceuticals

NasdaqGS:ALNY

US$16.3b

Sarepta Therapeutics

NasdaqGS:SRPT

US$5.5b

Ionis Pharmaceuticals

NasdaqGS:IONS

US$4.2b

Price History & Performance

Summary of all time highs, changes and price drops for BioMarin Pharmaceutical
Historical stock prices
Current Share PriceUS$84.65
52 Week HighUS$92.17
52 Week LowUS$71.59
Beta0.49
1 Month Change-5.89%
3 Month Change14.80%
1 Year Change-3.80%
3 Year Change-11.31%
5 Year Change-2.21%
Change since IPO544.95%

Recent News & Updates

Jan 11

BioMarin's Win In Phase 3 Hemophilia Study Makes Its Investment Case Stronger

BioMarin achieves primary endpoint of 2-year annualized bleeding rate in phase 3 GENEr8-1 study using the gene therapy valoctocogene roxaparvovec for severe Hemophilia A patients. BLA filing and European reviews of valoctocogene roxaparvovec for severe Hemophilia A patients are expected in 1st half of 2022. The Hemophilia A market is expected to be worth $18.1 billion by 2027. About 50% to 60% of Hemophilia patients are of the severe type. Company guided higher for total 2021 sales for all its drugs and believes that in 2022 it will attain GAAP profitability.

Shareholder Returns

BMRNUS BiotechsUS Market
7D-6.2%-7.4%-6.1%
1Y-3.8%-22.0%4.2%

Return vs Industry: BMRN exceeded the US Biotechs industry which returned -20% over the past year.

Return vs Market: BMRN underperformed the US Market which returned 6.6% over the past year.

Price Volatility

Is BMRN's price volatile compared to industry and market?
BMRN volatility
BMRN Average Weekly Movement5.5%
Biotechs Industry Average Movement10.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: BMRN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BMRN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19963,059Jean-Jacques Bienaimehttps://www.biomarin.com

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder.

BioMarin Pharmaceutical Fundamentals Summary

How do BioMarin Pharmaceutical's earnings and revenue compare to its market cap?
BMRN fundamental statistics
Market CapUS$15.54b
Earnings (TTM)US$15.92m
Revenue (TTM)US$1.85b

976.5x

P/E Ratio

8.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMRN income statement (TTM)
RevenueUS$1.85b
Cost of RevenueUS$1.11b
Gross ProfitUS$743.56m
ExpensesUS$727.65m
EarningsUS$15.92m

Valuation

Is BioMarin Pharmaceutical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BMRN ($84.65) is trading below our estimate of fair value ($187.13)

Significantly Below Fair Value: BMRN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BMRN is poor value based on its PE Ratio (976.5x) compared to the US Biotechs industry average (23x).

PE vs Market: BMRN is poor value based on its PE Ratio (976.5x) compared to the US market (16.7x).


Price to Earnings Growth Ratio

PEG Ratio: BMRN is poor value based on its PEG Ratio (18.1x)


Price to Book Ratio

PB vs Industry: BMRN is overvalued based on its PB Ratio (3.6x) compared to the US Biotechs industry average (2x).


Future Growth

How is BioMarin Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

53.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMRN's forecast earnings growth (53.9% per year) is above the savings rate (2%).

Earnings vs Market: BMRN's earnings (53.9% per year) are forecast to grow faster than the US market (13.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BMRN's revenue (18.3% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: BMRN's revenue (18.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (14.9%).


Past Performance

How has BioMarin Pharmaceutical performed over the past 5 years?

76.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BMRN has a large one-off loss of $8.9M impacting its September 30 2021 financial results.

Growing Profit Margin: BMRN's current net profit margins (0.9%) are lower than last year (45.7%).


Past Earnings Growth Analysis

Earnings Trend: BMRN has become profitable over the past 5 years, growing earnings by 76% per year.

Accelerating Growth: BMRN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BMRN had negative earnings growth (-98.1%) over the past year, making it difficult to compare to the Biotechs industry average (11%).


Return on Equity

High ROE: BMRN's Return on Equity (0.4%) is considered low.


Financial Health

How is BioMarin Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: BMRN's short term assets ($2.3B) exceed its short term liabilities ($514.9M).

Long Term Liabilities: BMRN's short term assets ($2.3B) exceed its long term liabilities ($1.2B).


Debt to Equity History and Analysis

Debt Level: BMRN has more cash than its total debt.

Reducing Debt: BMRN's debt to equity ratio has reduced from 25.5% to 25.3% over the past 5 years.

Debt Coverage: BMRN's debt is well covered by operating cash flow (26%).

Interest Coverage: Insufficient data to determine if BMRN's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is BioMarin Pharmaceutical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Jean-Jacques Bienaime (68 yo)

16.67yrs

Tenure

US$18,119,133

Compensation

Mr. Jean-Jacques Bienaime, MBA, serves as a Member of Strategic Advisory Board at Longwood Fund. He has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Direct...


CEO Compensation Analysis

Compensation vs Market: Jean-Jacques's total compensation ($USD18.12M) is above average for companies of similar size in the US market ($USD11.42M).

Compensation vs Earnings: Jean-Jacques's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BMRN's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: BMRN's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BMRN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioMarin Pharmaceutical Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BioMarin Pharmaceutical Inc.
  • Ticker: BMRN
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$15.541b
  • Shares outstanding: 183.59m
  • Website: https://www.biomarin.com

Number of Employees


Location

  • BioMarin Pharmaceutical Inc.
  • 770 Lindaro Street
  • San Rafael
  • California
  • 94901
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:33
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.